Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP14 | P50281 | 1/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 8/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350555 | 0.89 | MAOB (0.60) | MMP1MMP2MMP9MMP14ADAM17 | |
| SCHEMBL6438683 | 0.89 | NR4A2 (0.64) | MMP1MMP2MMP9MMP14ADAM17 | |
| SCHEMBL3504082 | 0.88 | MAOB (0.64) | MMP1MMP2MMP9MMP14ADAM17 | |
| SCHEMBL4345295 | 0.87 | LTA4H (0.71) | MMP1MMP2MMP9MMP14ADAM17 | |
| SCHEMBL3505091 | 0.86 | MAOB (0.60) | NR4A2MAOBPARP10MAOA | |
| SCHEMBL31703476 | 0.86 | NR4A2 (0.60) | MMP1MMP2MMP9MMP14ADAM17 | |
| Hydrochloric Acid SCHEMBL5618518 | 0.86 | LTA4H (0.69) | MMP1MMP2MMP9MMP14ADAM17 | |
| SCHEMBL4332971 | 0.83 | NR4A2 (0.56) | MMP1MMP2MMP9MMP14ADAM17 | |
| SCHEMBL24968494 | 0.80 | NR4A2 (0.59) | NR4A2MAOBPARP10PPARAGSK3B | |
| SCHEMBL27619656 | 0.80 | MAOB (0.61) | NR4A2MAOBPARP10PPARAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | claimed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | claimed |
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| EP-1511718-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | MMP1 2674/4885MMP2 1932/4885MMP9 2778/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MMP1 539/4885MMP2 542/4885MMP9 489/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | MMP1 2543/4885MMP2 1641/4885MMP9 2469/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | MMP1 2767/4885MMP2 1737/4885MMP9 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.